ANA URRIOLA: Open Payments
NPI 1235361106 · PATERSON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,341 in 72 payments from 16 companies in 2025. Trend: 2023 $1,417 · 2024 $1,665 · 2025 $1,341
Food & beverage: $1,341
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $240 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $197 |
| Novo Nordisk Inc | 11 | $183 |
| GlaxoSmithKline, LLC. | 8 | $141 |
| Kowa Pharmaceuticals America, Inc. | 7 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $98 |
| Amgen Inc. | 4 | $63 |
| Astellas Pharma US Inc | 3 | $58 |
| ABBVIE INC. | 3 | $53 |
| Madrigal Pharmaceuticals | 3 | $51 |
Products named: AIRSUPRA, JARDIANCE, Ozempic, TRELEGY ELLIPTA, ZORYVE, XIFAXAN, Veozah, REZDIFFRA.
Industry payments across NJ — which companies pay providers there.
